NCT07196111 2025-09-29
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
9 trialsNCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT05651178 2025-01-07
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06532643 2024-09-19
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT04541108 2024-04-18
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Recruiting
NCT05979857 2023-11-22
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Salarius Pharmaceuticals, LLC
Phase EARLY_PHASE1 Not yet recruiting
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04156178 2019-11-12
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown